Literature DB >> 24627607

TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.

Ming Bai1, Xing-Shun Qi1, Zhi-Ping Yang1, Man Yang1, Dai-Ming Fan1, Guo-Hong Han1.   

Abstract

AIM: To compare the liver transplantation-free (LTF) survival rates between patients who underwent transjugular intrahepatic portosystemic shunts (TIPS) and those who underwent paracentesis by an updated meta-analysis that pools the effects of both number of deaths and time to death.
METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched from the inception to October 2012. LTF survival, liver transplantation, liver disease-related death, non-liver disease-related death, recurrent ascites, hepatic encephalopathy (HE) and severe HE, and hepatorenal syndrome were assessed as outcomes. LTF survival was estimated using a HR with a 95%CI. Other outcomes were estimated using OR with 95%CIs. Sensitivity analyses were performed to assess the effects of potential outliers in the studies according to the risk of bias and the study characteristics.
RESULTS: Six randomized controlled trials with 390 patients were included. In comparison to paracentesis, TIPS significantly improved LTF survival (HR = 0.61, 95%CI: 0.46-0.82, P < 0.001). TIPS also significantly decreased liver disease-related death (OR = 0.62, 95%CI: 0.39-0.98, P = 0.04), recurrent ascites (OR = 0.15, 95%CI: 0.09-0.24, P < 0.001) and hepatorenal syndrome (OR = 0.32, 95%CI: 0.12-0.86, P = 0.02). However, TIPS increased the risk of HE (OR = 2.95, 95%CI: 1.87-4.66, P = 0.02) and severe HE (OR = 2.18, 95%CI: 1.27-3.76, P = 0.005).
CONCLUSION: TIPS significantly improved the LTF survival of cirrhotic patients with refractory ascites and decreased the risk of recurrent ascites and hepatorenal syndrome with the cost of increased risk of HE compared with paracentesis. Further studies are warranted to validate the survival benefit of TIPS in clinical practice settings.

Entities:  

Keywords:  Ascites; Meta-analysis; Paracentesis; Survival; Transjugular intrahepatic portosystemic shunt

Mesh:

Year:  2014        PMID: 24627607      PMCID: PMC3949280          DOI: 10.3748/wjg.v20.i10.2704

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

Review 2.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

Review 3.  Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.

Authors:  P Deltenre; P Mathurin; S Dharancy; R Moreau; P Bulois; J Henrion; F R Pruvot; O Ernst; J C Paris; D Lebrec
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

4.  Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

Authors:  Gennaro D'Amico; Angelo Luca; Alberto Morabito; Roberto Miraglia; Mario D'Amico
Journal:  Gastroenterology       Date:  2005-10       Impact factor: 22.682

5.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.

Authors:  Lesley Wood; Matthias Egger; Lise Lotte Gluud; Kenneth F Schulz; Peter Jüni; Douglas G Altman; Christian Gluud; Richard M Martin; Anthony J G Wood; Jonathan A C Sterne
Journal:  BMJ       Date:  2008-03-03

6.  A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

Authors:  Agustín Albillos; Rafael Bañares; Mónica González; María-Vega Catalina; Luis-Miguel Molinero
Journal:  J Hepatol       Date:  2005-07-05       Impact factor: 25.083

7.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

8.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

Review 9.  Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.

Authors:  Francesco Salerno; Monica Guevara; Mauro Bernardi; Richard Moreau; Florence Wong; Paolo Angeli; Guadalupe Garcia-Tsao; Samuel S Lee
Journal:  Liver Int       Date:  2010-05-21       Impact factor: 5.828

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  28 in total

1.  Small-diameter TIPS combined with splenic artery embolization in the management of refractory ascites in cirrhotic patients.

Authors:  Nathan E Frenk; Teodora Bochnakova; Suvranu Ganguli; Nathaniel Mercaldo; Andrew S Allegretti; Daniel S Pratt; Kei Yamada
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

Review 2.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

3.  Biomarkers of Renal Injury in Cirrhosis: Association with Acute Kidney Injury and Recovery after Liver Transplantation.

Authors:  Ashwani K Singal; Bradford Jackson; Glauber B Pereira; Kirk B Russ; Paul Stephen Fitzmorris; Donny Kakati; Page Axley; Sujan Ravi; Toni Seay; Satish P Ramachandra Rao; Ravindra Mehta; Yong-Fang Kuo; Karan P Singh; Anupam Agarwal
Journal:  Nephron       Date:  2017-09-02       Impact factor: 2.847

4.  Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.

Authors:  Mona Ascha; Mohamad Hanouneh; Mustafa S Ascha; Nizar N Zein; Mark Sands; Rocio Lopez; Ibrahim A Hanouneh
Journal:  Dig Dis Sci       Date:  2016-05-06       Impact factor: 3.199

5.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

6.  Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.

Authors:  Valerie Will; Susana G Rodrigues; Guido Stirnimann; Andrea De Gottardi; Jaime Bosch; Annalisa Berzigotti
Journal:  United European Gastroenterol J       Date:  2020-06-26       Impact factor: 4.623

Review 7.  Hepatorenal Syndrome: Physiology, Diagnosis and Management.

Authors:  Joseph Chmielewski; Robert J Lewandowski; Haripriya Maddur
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

Review 8.  Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature.

Authors:  Ana Cecilia Burgos; Bartley Thornburg
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

Review 9.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

10.  Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review.

Authors:  Chunze Zhou; Changlong Hou; Delei Cheng; Wenjing Tang; Weifu Lv
Journal:  Int J Clin Exp Med       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.